Galena Shares Under Pressure
Shares in Galena Biopharma Inc. (Ticker: GALE) slumped on Wednesday, dropping more than 15% to $4.38 during the first hour of the trading session after an article on The Street noted recent insider selling, the publication of a number of articles on Seeking Alpha (SA) that were designed to benefit Galena?s share price, and the subsequent removal of those articles earlier this week.
The full article by Adam Feuerstein is available on thestreet.com: http://bit.ly/1hc4nn3
Options traders were quick out of the gate this morning to brace for possible further selling pressure on Galena. The most traded contracts on GALE thus far in the session are the Feb $5.0 strike puts, which have traded roughly 4,500 times against open interest of 1,336 contracts. It looks like most of the in-the-money put options were purchased at an average premium of $0.60 each. Put buyers stand ready to profit at expiration next week should shares in Galena settle below the average breakeven point on the downside at $4.40.
Overall options volume on the stock is more than two times the average daily level as of 11:30 a.m. EST, with around 15,000 contracts in play on GALE versus an average daily reading of around 7,100 contracts.
—————————————————————————————————-
Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither Interactive Brokers LLC nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither IB nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance is not necessarily indicative of future results.
This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only correct as of the stated date of their issue. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.